Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study (BMC Cancer, (2021), 21, 1, (1021), 10.1186/s12885-021-08738-z)

Mustafa ErmanBivas BiswasPongwut DanchaivijitrLingwu ChenYoke Fui WongTarek HashemChun Sen LimBulent KarabulutHsiao Jen ChungChandrasekhar ChikatapuSara InglesKhemaies SlimaneRavindran KanesvaranSiriraj HospitalNational Yang Ming Chiao Tung UniversityThe First Affiliated Hospital, Sun Yat-sen UniversityNational Cancer Centre, SingaporeEge ÜniversitesiHacettepe ÜniversitesiNovartis Pharma S.A.S.Novartis International AGMedical OncologyRadiotherapy and OncologyMedical OncologyNovartis Healthcare Pvt. Ltd.Hospital Sultan Ismail2022-08-042022-08-042021-12-01BMC Cancer. Vol.21, No.1 (2021)147124072-s2.0-85118981336https://repository.li.mahidol.ac.th/handle/20.500.14594/75908Following publication of the original article [1], the authors identified an error in the author names of Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen and Chandrasekhar Chikatapu. The given names and family names were erroneously transposed. Further to this, figure 1 has been updated. The line colors in “C” section for “Poor” and “Unknown” have been changed to align with Figure B and legend to match the line colors. The author group has been updated above and the original article [1] has been corrected.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineCorrection to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study (BMC Cancer, (2021), 21, 1, (1021), 10.1186/s12885-021-08738-z)ErratumSCOPUS10.1186/s12885-021-08848-8